Implementierungsleitfaden Therapieziele Onkologie - Local Development build (v1.0.0-ballot) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

• Narrative Content
• XML
• JSON

: HER2/neu-Status – negativ (Beispiel)

Raw json | Download

{
  "resourceType" : "Observation",
  "id" : "ObsHER2Mamma",
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"en\" lang=\"en\"><hr/><p><b>English</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: Observation ObsHER2Mamma</b></p><a name=\"en-ObsHER2Mamma\"> </a><a name=\"en-hcObsHER2Mamma\"> </a><p><b>status</b>: Final</p><p><b>code</b>: <span title=\"Codes:{http://loinc.org 48676-1}\">HER2 Ag [Interpretation] in Tissue</span></p><p><b>subject</b>: <a href=\"Patient-PatientinMamma.html\">Sabine Baumann  Female, DoB: 1977-06-24</a></p><p><b>effective</b>: 2025-09-17</p><p><b>value</b>: <span title=\"Codes:{http://loinc.org LA6577-6}, {https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-mamma-her2neu-status-obds N}, {https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-mamma-her2neu-status-leitlinie negativ}\">Negative</span></p><p><b>note</b>: </p><blockquote><div><p>Immunhistochemie 1+ → HER2-negativ; keine In-situ-Hybridisierung erforderlich.</p>\n</div></blockquote><p><b>specimen</b>: <a href=\"Specimen-SpecimenBiopsieMamma.html\">Specimen: status = available; type = Specimen from breast obtained by core needle biopsy</a></p></div>"
  },
  "status" : "final",
  "code" : {
    "coding" : [
      {
        "system" : "http://loinc.org",
        "code" : "48676-1",
        "display" : "HER2 Ag [Interpretation] in Tissue"
      }
    ]
  },
  "subject" : {
    🔗 "reference" : "Patient/PatientinMamma"
  },
  "effectiveDateTime" : "2025-09-17",
  "valueCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://loinc.org",
        "code" : "LA6577-6",
        "display" : "Negative"
      },
      {
        "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-mamma-her2neu-status-obds",
        "code" : "N",
        "display" : "negativ"
      },
      {
        "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-mamma-her2neu-status-leitlinie",
        "code" : "negativ",
        "display" : "HER2-negativ"
      }
    ]
  },
  "note" : [
    {
      "text" : "Immunhistochemie 1+ → HER2-negativ; keine In-situ-Hybridisierung erforderlich."
    }
  ],
  "specimen" : {
    🔗 "reference" : "Specimen/SpecimenBiopsieMamma"
  }
}